The 340B Drug Pricing Program (“340B Program”) space continues to be a hive of activity. While 340B stakeholders continue to litigate ongoing manufacturer contract pharmacy restrictions, states ...
Biosimilar drugs—lower-cost alternatives to expensive biologic drugs—have the potential to slow the growth of US drug spending. However, rates of biosimilar uptake have varied across hospital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results